Tests SCT520FF in adults with wet age-related macular degeneration
Tests SCT520FF, a new eye injection, in adults with wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Key facts
- Where
- Tianjing, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 80 years old?
Source: NCT06672536, who can take part
Where in China
- Tianjin Medical University Eye HospitalTianjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sinocelltech Ltd.
- Trial code
- NCT06672536
- Record updated
- 4 September 2025
- Original description
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.Read full original descriptionShow less
A Multicenter, Dose-escalation and Dose-expansion, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy Characteristics of SCT520FF in Patients With Neovascular Age-related Macular Degeneration
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
Inclusion: Signed informed consent form; Age≥45 years, ≤80 years，male or femal; The study eye must meet the following criteria: Diagnosis of nAMD;Active MNV lesions secondary to nAMD; Total area of all types of lesions ≤12 optic disc areas; BCVA of the study eye 73~19 letters.
Exclusion: History of a cardiovascular and cerebrovascular events, including myocardial infarction, unstable angina pectoris, cerebrovascular accidents (including TIA), other thromboembolic diseases (such as thromboembolic angiitis, etc) within 6 months before randomization; Evidence of significant uncontrolled concomitant diseases; Participated in any drug (other than vitamins and minerals) or device clinical trials within 3 months or the duration of 5 half-lives of the study drug (which is longer) before randomization and have used the test drug or received device treatment; The study eye has any eye diseases or medical history other than nAMD that may affect central vision and/or macular examine; Active inflammation or infection in either eye before randomization; Known allergy to any component of the study intervention or history of allergy to fluorescein or indocyanine green, any anesthetics or antimicrobial agents used during the course of the study; Macular-related retinal pigment epithelial tears in the study eye; scar, fibrosis, atrophy or dense subfoveal exudation involving the fovea in the study eye; Significant APD or opacity of the refractive medium and miosis in the study eye that affect visual acuity or fundus examination; Aphakia (except intraocular lens) or posterior capsular rupture of the lens in the study eye; MNV caused by non-nAMD exists in the study eye ; Abnormal liver and kidney function; Poorly-controlled blood pressure before randomization; Pregnant, lactating women who can not take contraceptive measures during the trial.